Choong ANG Vaccine Laboratory중앙백신
072020 · KOSDAQ · ₩072020 · 중앙백신
₩8,870▲ ₩40 (0.45%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 48.9% | 48.7% | 46.7% | 51.4% | 47.8% | 46.5% |
| Operating margin | 14.2% | 13.2% | 12.6% | 16.7% | 11.2% | 11.2% |
| Net margin | 14.0% | 12.5% | 15.0% | 14.3% | 10.5% | 18.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.6% | +7.6% | +8.9% | +6.7% | −4.0% | — |
| Operating income growth | +5.5% | +12.5% | −17.7% | +59.2% | −4.3% | — |
| Net income growth | +9.9% | −10.1% | +14.2% | +45.6% | −46.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 6.3% | 5.9% | 6.7% | 6.1% | 4.4% | 8.2% |
| Return on assets | 5.5% | 5.0% | 5.6% | 5.1% | 3.6% | 6.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 16.1% | 16.6% | 18.7% | 19.8% | 20.5% | 21.5% |
| Net debt to equity | −19.2% | −16.3% | −19.6% | −16.6% | 4.6% | — |
| Current ratio | 431.4% | 426.8% | 436.7% | 399.6% | 297.1% | 276.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Choong ANG Vaccine Laboratory / 중앙백신 / 072020 / KRX:072020
Source: KRX statistical information